The study of plumbagin on suppressing the proliferation of non-small cell lung cancer

doi:10.3877/cma.j.issn.2095-5782.2024.02.004

Abstract

Abstract:

Objective

To explore the tumour suppressing efficacy of plumbagin (PLB) on non-small cell lung cancer (NSCLC).

Methods

We used CCK-8 assay to detecte the effect of PLB on the proliferation of LLC1 cells and established a Lewis lung carcinoma model to evaluate the efficacy and biosafety of PLB in the treatment of subcutaneous tumor in mice.

Results

CCK-8 results showed that PLB significantly suppressed the proliferation of LLC1 cells in a time- and dose-dependent manner and its mechanisms were related to apoptosis and ferroptosis. In Lewis lung carcinoma model, PLB treatment group exhibited stronger antitumor effects versus the control group. The H&E results showed that, compared to the control group, there was an increase in cell nucleus rupture and tissue necrosis area with PLB treatment.

Conclusion

Both the results of cell and animal experiments confirmed that PLB suppressed the growth and proliferation of NSCLC cells, which may be related to cell apoptosis and ferroptosis. This provides a preclinical basis for treating NSCLC with PLB and promotes the development of new drugs.

Key words: Plumbagin, Non-small cell lung cancer, Ferroptosis, Apoptosis

Meisi Liang, Huimin Lan, Ting Yu, Shengqiao Li. The study of plumbagin on suppressing the proliferation of non-small cell lung cancer[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(02): 120-125.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2024.02.004

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2024/V12/I02/120

Figures/Tables 7

References 20

[1]	Chen P, Liu Y, Wen Y, et al. Non-small cell lung cancer in China[J]. Cancer Commun (Lond), 2022, 42(10): 937-970.
[2]	Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer[J]. Lancet, 2021, 398(10299): 535-554.
[3]	Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy[J]. J Hematol Oncol, 2019, 12(1): 134.
[4]	Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors[J]. Cancer Cell, 2020, 37(4): 443-455.
[5]	Wang S, Fu JL, Hao HF, et al. Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy[J]. Pharmacol Res, 2021, 170: 105728.
[6]	Lin CL, Yu CI, Lee TH, et al. Plumbagin induces the apoptosis of drug-resistant oral cancer in vitro and in vivo through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction[J]. Phytomedicine, 2023, 111: 154655.
[7]	Chen Y, Zhao C, Liu X, et al. Plumbagin ameliorates liver fibrosis via a ROS-mediated NF-small ka, CyrillicB signaling pathway in vitro and in vivo[J]. Biomed Pharmacother, 2019, 116: 108923.
[8]	Kong X, Luo J, Xu T, et al. Plumbagin enhances TRAIL-induced apoptosis of human leukemic Kasumi-1 cells through upregulation of TRAIL death receptor expression, activation of caspase-8 and inhibition of cFLIP[J]. Oncol Rep, 2017, 37(6): 3423-3432.
[9]	Jiang ZB, Xu C, Wang W, et al. Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8(+) T cells [J]. Pharmacol Res, 2021, 169: 105656.
[10]	Leader AM, Grout JA, Maier BB, et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification[J]. Cancer Cell, 2021, 39(12): 1594-1609 e12.
[11]	Wang XR, Jiang ZB, Xu C, et al. Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response[J]. Pharmacol Res, 2022, 179: 106198.
[12]	Xu C, Jiang ZB, Shao L, et al. beta-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer[J]. Pharmacol Res, 2023, 191: 106739.
[13]	Yao L, Yan D, Jiang B, et al. Plumbagin is a novel GPX4 protein degrader that induces apoptosis in hepatocellular carcinoma cells[J]. Free Radic Biol Med, 2023, 203: 1-10.
[14]	Zhang R, Wang Z, You W, et al. Suppressive effects of plumbagin on the growth of human bladder cancer cells via PI3K/AKT/mTOR signaling pathways and EMT[J]. Cancer Cell Int, 2020, 20: 520.
[15]	Sakunrangsit N, Ketchart W. Plumbagin inhibits cancer stem-like cells, angiogenesis and suppresses cell proliferation and invasion by targeting Wnt/beta-catenin pathway in endocrine resistant breast cancer[J]. Pharmacol Res, 2019, 150: 104517.
[16]	Li T, Lv M, Chen X, et al. Plumbagin inhibits proliferation and induces apoptosis of hepatocellular carcinoma by downregulating the expression of SIVA[J]. Drug Des Devel Ther, 2019, 13:1289-1300.
[17]	Kajarabille N, Latuned-Data GO. Programmed cell-death by ferroptosis: antioxidants as mitigators [J]. Int J Mol Sci, 2019, 20(19):4968.
[18]	Hu Q, Zhu W, Du J, et al. A GPX4-targeted photosensitizer to reverse hypoxia-induced inhibition of ferroptosis for non-small cell lung cancer therapy[J]. Chem Sci, 2023, 14(34): 9095-9100.
[19]	Li D, Li Y. The interaction between ferroptosis and lipid metabolism in cancer[J]. Signal Transduct Target Ther, 2020, 5(1): 108.
[20]	Li YC, He SM, He ZX, et al. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells[J]. Cancer Lett, 2014, 344(2): 239-259.

Please choose a citation manager

Content to export